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■ RESEARCH LETTER ■
Synchronous primary ovarian and endometrial cancers
are quite unusual based on our previous experience
[1,2]. Confirmative diagnosis depends on the patho-
logic recognition of different histologic patterns. Al-
though some researchers have tried to determine the
underlying mechanisms for the development of synchro-
nous tumors using advanced molecular or clonal analy-
sis, the etiologies of such tumors remain unclear [3–6].
A recently proposed hypothesis suggests that the etiol-
ogy of synchronous cancers is related to the embryologi-
cally similar organs that develop synchronous neoplasms
when they are simultaneously subjected to carcinogens.
However, the overall prognosis of patients with syn-
chronous primary ovarian and endometrial cancers was
reported to be better than those with metastatic tumors
[1,2,7,8]. Conservative preservation of fertility is often
considered for young premenopausal women [9]. In this
case report, we discuss the management of a young fe-
male patient with synchronous primary ovarian and en-
dometrial cancers, with fair prognosis, at our hospital.
We present a 31-year-old, gravida 0, para 0, married
woman who visited our outpatient clinic because of an
incidental finding of elevated CA-125 (300 U/mL) dur-
ing a routine health examination in April, 2006. She was
in good health before this admission and received reg-
ular Papanicolaou tests at a local hospital. Her men-
strual cycle was regular without dysmenorrhea, and
the interval was about 35–40 days with a moderate
amount of blood. Only one episode of intermenstrual
vaginal spotting was noted 3 months before this admis-
sion. She visited her local hospital, and transvaginal
sonography revealed an endometrial hyperplasia, which
resolved spontaneously without any medication. At pres-
entation to our obstetrics/gynecology clinic, transvaginal
sonography showed one heterogeneous tumor of 6.8 ×
6.6 × 5.2 cm in size in the right ovary, one small tumor
in her left ovary, and heterogeneous endometrium with
a thickness of 17 mm.
The patient was admitted on May 5th, 2006 to the
National Taiwan University Hospital (NTUH), where a
right ovarian tumor (5.9 × 3.9 cm) with a small amount
of ascites and one 2.8-cm hepatic hemangioma in the
S7 lobe were detected by abdominal and pelvic com-
puted tomography. The CA-125 concentration was
rechecked and was 1,944.61 U/mL. The hemogram
showed anemia (hemoglobin, 9.5 g/dL). After a thor-
ough explanation and discussion, she decided to undergo
exploratory surgery. However, she also strongly wished
to preserve her uterus for future reproductive potential.
During the operation performed on May 9th, 2006,
the right ovarian tumor was removed and frozen for
pathologic assessment. In addition, a small solid com-
ponent was detected on the surface of her left ovary
but was not enlarged, and there were no indurated lymph
nodes. The pathologic analysis of the excised right ovar-
ian tumor specimen revealed the potential for low-grade
malignant changes. A conservative staging operation,
which involved bilateral salpingo-oophorectomy, omen-
tectomy and bilateral pelvic lymph nodes dissection,
was conducted via a low vertical incision. Meanwhile,
fractional dilatation and curettage was also performed
because of the ultrasound finding of a thickened endo-
metrium. One closed wound vacuum drain tube was in-
serted at the cul-de-sac for drainage with a slight amount
of discharge. The postoperative course was good, and
a small amount of light-pink-colored fluid was drained.
The final pathology report revealed right ovarian
endometrioid adenocarcinoma and left ovarian mixed
endometrioid adenocarcinoma with clear cell adeno-
carcinoma. Ascites cytology was positive for malignant
cells. Furthermore, the endometrial curetting showed
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low-grade endometrioid adenocarcinoma. After discus-
sion with our pathologist, early-stage synchronous pri-
mary ovarian (stage Ic) and endometrial (stage Ia, grade
I) cancer was diagnosed. This patient underwent the
second stage of the total abdominal hysterectomy on
May 19th, 2006.
On May 27th, 2006, adjuvant chemotherapy of pacli-
taxel and carboplatin was prescribed based on our own
experience [2]. A portacath insertion was completed
via the right subclavian vein on June 20th, 2006, and
her treatment regimen was switched to cyclophos-
phamide and carboplatin because of a severe allergic
skin reaction that was possibly induced by paclitaxel.
The five courses of cyclophosphamide and carbo-
platin therapy were completed on October 15th, 2006.
Follow-up examination results revealed that CA-125
had decreased to a normal level since the second
course of chemotherapy (Figure 1). Her general condi-
tion was good, except for postsurgical menopausal
syndromes, which resolved after treatment with 17β-
estradiol gel (transdermal) and dydrogesterone (oral)
as hormone replacement therapy. A positron emission
tomography scan performed on February 14th, 2007
showed no evidence of abnormal fluorodeoxyglucose
metabolic lesions. In addition, a computed tomography
scan performed on April 16th, 2008 revealed no local
recurrence. The following Papanicolaou test results
were within normal range.
According to the cancer registration record (from
1977 to 1994) at the NTUH, of the 322 patients with
endometrial cancer and 421 patients with ovarian cancer,
only six patients had synchronous primary endometrial
and ovarian cancers [1]. According to other data from
the NTUH (from 1977 to 2005), the incidence of syn-
chronous endometrial and ovarian cancers was 2.7% 
in patients with ovarian cancer and 3.3% in patients 
with endometrial cancers [2]. By comparison, in the
Gynecologic Oncology Group Study (from 1985 to 1991)
[8], the incidence of synchronous endometrial and ovar-
ian cancers was much higher, being 10% in patients with
ovarian cancer and 5% in patients with endometrial
cancers. This may be related to the fact that the findings
reported by Chiang et al [2] represent cases encoun-
tered at a single institute (NTUH) and only included cases
with a confirmed pathologic diagnosis. Racial differences
may offer another reason for these discrepancies [2].
According to the pathologic findings, endometri-
oid adenocarcinomas with similar histologic charac-
teristics were the most common types to be reported.
Until now, very few researchers have reported patients
with synchronous primary endometrial and ovarian can-
cer with different or mixed histologic types, which may
be related to their worse prognosis compared with
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Figure 1. Levels of the tumor marker CA-125 before and
after surgery, and after chemotherapy.
endometrioid cancers [10–12]. The average disease-free
interval for patients with synchronous tumors was
around 35–144 months (median, 94.2 months) [1].
The outcomes at our institute were similar to those
reported elsewhere [7,8], and the estimated 5-year and
10-year survival rates were 85.9% and 80.3%, respec-
tively, according to the previously published statistics for
our hospital [8]. Until now, no statistical analyses have
provided strong evidence indicating age, stage of ovar-
ian cancer or grade of endometrial cancer as significant
prognostic factors.
When the pathologic findings reveal two different
histologic types, the confirmatory diagnosis of syn-
chronous tumors is not difficult. However, when the
pathologic study reveals similar types, the differentia-
tion between the two separate primary cancers or one
single advanced cancer with metastasis is much more
difficult. Based on the clinical observations and patho-
logic and molecular analysis (including immunohisto-
logic and DNA analysis), most synchronous primary
tumors can be diagnosed correctly and definitively.
Furthermore, by applying standardized criteria [10] [(1)
both tumors are confined to primary sites; (2) no direct
extension between the tumors; (3) no lymphovascular
tumor emboli; (4) no or only superficial myometrial
invasion of the endometrial lesion; and (5) no distant
metastasis], we could still differentiate the two cancers.
According to the pathologic report, there was endo-
metrioid adenocarcinoma in the presence of atypical
hyperplasia; therefore, the diagnosis should favor pri-
mary endometrial cancer (Figure 2). In our experience,
ovarian endometrioid adenocarcinoma coexisting with
clear cell carcinoma (Figure 3) is relatively common. In
the present case, we noted endometriosis in the left
ovary, which might explain the primary ovarian cancer
in our patient (Figure 4).
By applying the criteria above and the pathologic
findings, our patient was diagnosed with synchronous
primary ovarian and endometrial cancers. According to
some case reports, up to 80–86% of patients with syn-
chronous tumors were diagnosed after the initial presen-
tation of abnormal vaginal bleeding [2,8]. The mean age
for definite diagnosis was 47–49 years [2,8], which was
younger than that of patients with either primary ovar-
ian or endometrial cancers. The medical history of this
patient revealed no evidence of previous polycystic
ovarian syndrome, infertility or endometriosis. There
was only one episode of intermenstrual vaginal spotting,
which resolved spontaneously. She was quite thin with
good nutrition and socioeconomic status. There was no
family history of gynecologic cancers.
A two-stage operation was initially planned and
conducted based on the patient’s wish to preserve her
reproductive function. Before this operation, we also
consulted an infertility specialist. Because of the high
potential of malignant changes and technical challenges,
we decided not to conduct oocyte or ovarian tissue
cryopreservation and preferred to preserve her uterus.
Except for one episode of vaginal spotting with slightly
thickened endometrium, without significant evidence
for an endometrial lesion, we did not perform a simple
diagnostic dilatation and curettage before surgery to
exclude endometrial cancer. After the first conservative
staging surgery with the final confirmed pathologic
report, this patient decided to undergo the second
debulking operation to complete the staging and started
adjuvant chemotherapy, even though the prognosis may
be better for most patients with synchronous tumors
than for those with metastasis. Overall, this patient com-
pleted six cycles of postoperative adjuvant chemotherapy
because of the mixed histologic types of endometrioid/
clear cell carcinoma of the left ovary; the patient expe-
rienced no significant side effects. At the time of writing,
there was no evidence of recurrence in this patient.
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Figure 2. (A) The endometrium showing a International Federation of Gynecology and Obstetrics grade 1 endometrioid ade-
nocarcinoma characterized by a complex glandular architecture without myometrial invasion (hematoxylin and eosin, 40×).
(B) Atypical endometrial hyperplasia lesion near the endometrioid adenocarcinoma, which is a sign for primary endometrial
cancer (hematoxylin and eosin, 100×).
Figure 3. Right ovarian endometrioid adenocarcinoma with
high-grade nuclei (hematoxylin and eosin, 40×).
Figure 4. Left ovarian endometrioid adenocarcinoma mixed
with clear cell carcinoma (hematoxylin and eosin, 200×).
Overall, a conservative staging operation is an
acceptable option for young women with early-stage
ovarian cancer who wish to preserve their reproductive
function. However, the possibility of synchronous pri-
mary ovarian and endometrial cancers should be 
considered, and the patients must be well informed,
particularly when history of abnormal uterine spotting
is found. The patient in this case report underwent
two-stage surgery for fertility preservation and adjuvant
chemotherapy because of the mixed histologic types;
the outcomes to date were good. We recommend that
for young female patients who wish to preserve their
reproductive function, even without high suspicion of
endometrial lesions, diagnostic dilatation and curettage
should be conducted preoperatively to aid treatment
planning.
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